WallStreetZenWallStreetZen

NASDAQ: NCNA
Nucana PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NCNA stock forecasts and price targets.

Forecast return on equity

Is NCNA forecast to generate an efficient return?

Company
-166,788.07%
Industry
7.64%
Market
141.17%
NCNA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NCNA forecast to generate an efficient return on assets?

Company
-136,000.99%
Industry
-9.8%
NCNA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NCNA earnings per share forecast

What is NCNA's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.22
Avg 2 year Forecast
-$2.60

NCNA revenue forecast

What is NCNA's revenue in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$12.2M

NCNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NCNA$2.13N/AN/A
SCNI$0.60N/AN/A
BDRX$3.47N/AN/A
ELAB$3.81N/AN/A
SPRC$4.24N/AN/A
View Top Biotech Stocks

Nucana Stock Forecast FAQ

What is NCNA's earnings growth forecast for 2026-2027?

(NASDAQ: NCNA) Nucana's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,471.9%.

Nucana's earnings in 2026 is -$39,137,333.On average, 6 Wall Street analysts forecast NCNA's earnings for 2026 to be -$25,356,808,253, with the lowest NCNA earnings forecast at -$24,362,097,186, and the highest NCNA earnings forecast at -$26,101,801,060.

In 2027, NCNA is forecast to generate -$54,099,379,906 in earnings, with the lowest earnings forecast at -$85,896,838,265 and the highest earnings forecast at -$19,349,003,130.

If you're new to stock investing, here's how to buy Nucana stock.

What is NCNA's revenue growth forecast for 2026-2027?

(NASDAQ: NCNA) Nucana's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 188.7%.

Nucana's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast NCNA's revenue for 2026 to be $0, with the lowest NCNA revenue forecast at $0, and the highest NCNA revenue forecast at $0.

In 2027, NCNA is forecast to generate $254,816,673,826 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $621,236,599,733.

What is NCNA's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: NCNA) forecast ROA is -136,000.99%, which is lower than the forecast US Biotechnology industry average of -9.8%.

What is NCNA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: NCNA) Nucana's current Earnings Per Share (EPS) is $0.00. On average, analysts forecast that NCNA's EPS will be -$1.22 for 2026, with the lowest EPS forecast at -$1.17, and the highest EPS forecast at -$1.25. In 2027, NCNA's EPS is forecast to hit -$2.60 (min: -$4.13, max: -$0.93).

What is NCNA's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: NCNA) forecast ROE is -166,788.07%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.